Teva Pharmaceutical Industries (TEVA) R&D In Process (2016 - 2017)
Historic R&D In Process for Teva Pharmaceutical Industries (TEVA) over the last 3 years, with Q3 2017 value amounting to $175.0 million.
- Teva Pharmaceutical Industries' R&D In Process fell 3055.56% to $175.0 million in Q3 2017 from the same period last year, while for Sep 2017 it was $427.0 million, marking a year-over-year increase of 6297.71%. This contributed to the annual value of $23.0 million for FY2009, which is N/A changed from last year.
- According to the latest figures from Q3 2017, Teva Pharmaceutical Industries' R&D In Process is $175.0 million, which was down 3055.56% from $252.0 million recorded in Q3 2016.
- In the past 5 years, Teva Pharmaceutical Industries' R&D In Process registered a high of $252.0 million during Q3 2016, and its lowest value of $10.0 million during Q1 2016.
- Over the past 3 years, Teva Pharmaceutical Industries' median R&D In Process value was $99.5 million (recorded in 2015), while the average stood at $115.2 million.
- Data for Teva Pharmaceutical Industries' R&D In Process shows a peak YoY increase of 3055.56% (in 2017) and a maximum YoY decrease of 3055.56% (in 2017) over the last 5 years.
- Teva Pharmaceutical Industries' R&D In Process (Quarter) stood at $24.0 million in 2015, then surged by 950.0% to $252.0 million in 2016, then tumbled by 30.56% to $175.0 million in 2017.
- Its R&D In Process was $175.0 million in Q3 2017, compared to $252.0 million in Q3 2016 and $10.0 million in Q1 2016.